Quantcast

Latest Boehringer Ingelheim Stories

2014-02-20 08:31:52

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase...

2014-02-19 23:27:36

As Reuters reported on February 13, Boehringer faces more than 2,000 US lawsuits claiming that Pradaxa caused severe and fatal bleeding. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) February 19, 2014 AttorneyOne.com, a recognized authority on law, updated the website recently and now, can...

2014-02-18 12:30:55

DURHAM, N.C., Feb. 18, 2014 /PRNewswire-iReach/ -- Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies, today announced the appointment of Patrick Phillips, D Phil, as Vice President, Clinical Affairs. (Photo: http://photos.prnewswire.com/prnh/20140218/MN66379) "We are delighted to add a clinical affairs executive with outstanding capabilities, deep global experience and expertise in the...

2014-02-15 23:00:34

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who suffered cerebral hemorrhage, gastrointestinal bleeding, and other serious bleeding events, allegedly due to Pradaxa. New York, New York (PRWEB) February 15, 2014 Boehringer Ingelheim has acknowledged being named a defendant in more than 2,000 Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) pending in U.S. courts that allege the company failed to warn patients about the potential for serious and uncontrollable...

2014-02-12 23:31:05

Roger C. Denton, Plaintiffs' Co-Lead Counsel in the Pradaxa® MDL, provides update for the Pradaxa Multidistrict Litigation (MDL 2385), particularly that numerous internal company documents have been unsealed and made publicly available. St. Louis, MO (PRWEB) February 12, 2014 On February 7, 2014, The New York Times reported that numerous documents have been made public in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products...

2014-02-08 23:01:19

The Firm is evaluating Pradaxa lawsuits on behalf of individual who allegedly suffered serous episodes of Pradaxa bleeding. New York, New York (PRWEB) February 08, 2014 As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to move forward, Bernstein Liebhard LLP notes that documents recently unsealed in the U.S. District Court, Southern District of Illinois, have shed new light on Boehringer Ingelheim’s marketing of the blood thinning drug. According to a report from The New...

2014-02-04 23:01:40

The Firm is evaluating Pradaxa lawsuits on behalf of clients who allegedly suffered life-threatening and uncontrollable internal hemorrhaging due to their use of the blood thinner. New York, New York (PRWEB) February 04, 2014 The federal judge overseeing thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) that allege the blood thinner caused patients to suffer life-threatening and uncontrollable internal hemorrhaging has granted a request by plaintiffs to unseal dozens of...

2014-01-30 12:28:26

Unique academic-industry partnership will include an IPF patient registry and biomarker bank RIDGEFIELD, Conn. and DURHAM, N.C., Jan. 30, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will...

2014-01-23 12:29:16

SAN DIEGO, Jan. 23, 2014 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in pharmaceutical formulation and clinical trial manufacturing, announced today its sponsorship of the 3rd Drug Formulation & Bioavailability Conference to be held in Boston, MA from January 27-29, 2014. Formex CSO Blair West, Ph.D. will be joined by distinguished speakers from Merck & Co, F Hoffman-La Roche, Novartis and Boehringer-Ingelheim for a discussion entitled "Accelerating Time to Market...

2014-01-13 04:21:01

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody(TM) research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'